RNAC Logo

Cartesian Therapeutics, Inc. (RNAC) 

NASDAQ
Market Cap
$497.61M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
57 of 776
Rank in Industry
45 of 433

Largest Insider Buys in Sector

RNAC Stock Price History Chart

RNAC Stock Performance

About Cartesian Therapeutics, Inc.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, …

Insider Activity of Cartesian Therapeutics, Inc.

Over the last 12 months, insiders at Cartesian Therapeutics, Inc. have bought $4.49M and sold $0 worth of Cartesian Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cartesian Therapeutics, Inc. have bought $4.49M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: SPRINGER TIMOTHY A () — $8.79M. BARABE TIMOTHY C (director) — $190,500.

The last purchase of 80,301 shares for transaction amount of $1.81M was made by SPRINGER TIMOTHY A () on 2024‑10‑04.

List of Insider Buy and Sell Transactions, Cartesian Therapeutics, Inc.

2024-10-04Purchase
80,301
0.4883%
$22.58$1.81M-10.83%
2024-10-03Purchase
119,906
0.6423%
$19.89$2.38M-4.12%
2024-10-02Purchase
5,514
0.0258%
$17.38$95,822+22.40%
2024-08-12Purchasedirector
7,500
0.0353%
$12.70$95,250+30.59%
2024-08-12Purchase
8,016
0.0378%
$12.72$101,968+30.59%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.